{"product_id":"600867ss-business-model-canvas","title":"Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS): Canvas Business Model","description":"\u003cp\u003eTonghua Dongbao Pharmaceutical Co., Ltd. is paving the way in the healthcare landscape with its innovative approach to diabetes treatments and high-quality pharmaceuticals. This dynamic company leverages key partnerships, advanced resources, and a deep commitment to patient care, all captured within its Business Model Canvas. Dive deeper into the elements driving its success, from valuable customer relationships to robust revenue streams, and discover how Tonghua Dongbao is shaping the future of medicine.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eTonghua Dongbao Pharmaceutical Co., Ltd. - Business Model: Key Partnerships\u003c\/h2\u003e\n\n\u003cp\u003eTonghua Dongbao Pharmaceutical Co., Ltd. engages in several strategic partnerships that bolster its market position and operational capabilities. These partnerships include collaborations with research institutions, raw material suppliers, distribution partners, and healthcare providers.\u003c\/p\u003e\n\n\u003ch3\u003eResearch Institutions\u003c\/h3\u003e\n\u003cp\u003eThe company collaborates with various research institutions to innovate and improve its pharmaceutical products. For instance, Tonghua Dongbao has worked with academic and research organizations to enhance its R\u0026amp;D capabilities, focusing on areas such as diabetes treatment and traditional Chinese medicine formulations. As of 2022, the company allocated approximately \u003cstrong\u003eRMB 345 million\u003c\/strong\u003e towards research and development, enabling it to leverage institutional expertise for product development.\u003c\/p\u003e\n\n\u003ch3\u003eRaw Material Suppliers\u003c\/h3\u003e\n\u003cp\u003eReliable supply chains are crucial for pharmaceutical companies. Tonghua Dongbao sources raw materials from numerous suppliers to ensure the quality and availability of its products. In 2021, the procurement cost for raw materials was reported at approximately \u003cstrong\u003eRMB 1.2 billion\u003c\/strong\u003e, emphasizing the importance of maintaining strong relationships with these suppliers. The company also aims to establish long-term contracts with suppliers to mitigate fluctuations in raw material costs.\u003c\/p\u003e\n\n\u003ch3\u003eDistribution Partners\u003c\/h3\u003e\n\u003cp\u003eDistribution is a critical factor for Tonghua Dongbao, as its products reach various markets. The company partners with regional and national distributors to enhance market penetration. In 2022, the distribution network was expanded to cover over \u003cstrong\u003e30 provinces\u003c\/strong\u003e in China, ensuring the availability of its pharmaceutical products across the country. The sales revenue generated through distribution in 2022 was approximately \u003cstrong\u003eRMB 2.5 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eYear\u003c\/th\u003e\n\u003cth\u003eRaw Material Procurement Cost (RMB)\u003c\/th\u003e\n\u003cth\u003eR\u0026amp;D Investment (RMB)\u003c\/th\u003e\n\u003cth\u003eDistribution Sales Revenue (RMB)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2021\u003c\/td\u003e\n\u003ctd\u003e1.2 billion\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2022\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e345 million\u003c\/td\u003e\n\u003ctd\u003e2.5 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eHealthcare Providers\u003c\/h3\u003e\n\u003cp\u003eTonghua Dongbao collaborates closely with healthcare providers to enhance product usage and gain feedback for improvements. The company has partnered with hospitals and clinics across China, offering support in the form of educational materials and product samples. In 2023, it was reported that approximately \u003cstrong\u003e1,200 hospitals\u003c\/strong\u003e were engaged in partnerships, which significantly influenced the company’s product adoption rates. The value generated from these collaborations is reflected in the rise in prescriptions for Tonghua's products, which increased by \u003cstrong\u003e15%\u003c\/strong\u003e year-over-year.\u003c\/p\u003e \n\n\u003cp\u003eThese key partnerships are fundamental to Tonghua Dongbao Pharmaceutical Co., Ltd.'s strategy for growth, innovation, and market presence, aligning its operational capabilities with industry demands.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eTonghua Dongbao Pharmaceutical Co., Ltd. - Business Model: Key Activities\u003c\/h2\u003e\n\n\u003cp\u003eThe key activities of Tonghua Dongbao Pharmaceutical Co., Ltd. play a crucial role in delivering its value proposition, focusing on pharmaceutical development, manufacturing, quality control, and regulatory compliance.\u003c\/p\u003e\n\n\u003ch3\u003ePharmaceutical Development\u003c\/h3\u003e\n\u003cp\u003eTonghua Dongbao invests significantly in research and development (R\u0026amp;D) to innovate and enhance its pharmaceutical products. In 2022, the company allocated approximately \u003cstrong\u003eRMB 1.24 billion\u003c\/strong\u003e to R\u0026amp;D, which accounted for around \u003cstrong\u003e10.6%\u003c\/strong\u003e of its total revenue. This investment supports the development of new formulations and therapeutic areas, particularly in the diabetes and orthopedic sectors.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing of Medicines\u003c\/h3\u003e\n\u003cp\u003eThe manufacturing process is central to the company's operations, with advanced facilities ensuring high production standards. In 2022, Tonghua Dongbao's production capacity reached \u003cstrong\u003e30 million units\u003c\/strong\u003e of various pharmaceutical products annually. Notably, the company's injectable production line contributes significantly, with a production volume of \u003cstrong\u003e10 million units\u003c\/strong\u003e for its flagship insulin products.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eManufacturing Facility\u003c\/th\u003e\n\u003cth\u003eLocation\u003c\/th\u003e\n\u003cth\u003eAnnual Capacity (Units)\u003c\/th\u003e\n\u003cth\u003eProduct Type\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInjectable Products Line\u003c\/td\u003e\n\u003ctd\u003eTonghua, Jilin Province\u003c\/td\u003e\n\u003ctd\u003e10 million\u003c\/td\u003e\n\u003ctd\u003eInsulin, Hormones\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOral Dosage Forms Line\u003c\/td\u003e\n\u003ctd\u003eTonghua, Jilin Province\u003c\/td\u003e\n\u003ctd\u003e20 million\u003c\/td\u003e\n\u003ctd\u003ePills, Tablets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSemi-solid Dosage Forms Line\u003c\/td\u003e\n\u003ctd\u003eTonghua, Jilin Province\u003c\/td\u003e\n\u003ctd\u003e5 million\u003c\/td\u003e\n\u003ctd\u003eGels, Creams\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eQuality Control\u003c\/h3\u003e\n\u003cp\u003eTonghua Dongbao prioritizes quality control throughout the manufacturing process. The company implements stringent quality assurance protocols, which include routine testing and validation of raw materials and finished products. As of Q2 2023, the company reported a \u003cstrong\u003e99.8%\u003c\/strong\u003e compliance rate with international quality standards, which is pivotal for maintaining product integrity and consumer trust.\u003c\/p\u003e\n\n\u003ch3\u003eRegulatory Compliance\u003c\/h3\u003e\n\u003cp\u003eEnsuring compliance with local and international regulations is essential for Tonghua Dongbao's operations. The company adheres to the \u003cstrong\u003eNational Medical Products Administration (NMPA)\u003c\/strong\u003e guidelines in China and the \u003cstrong\u003eU.S. Food and Drug Administration (FDA)\u003c\/strong\u003e regulations for exports. In 2022, the company successfully registered \u003cstrong\u003e15 new products\u003c\/strong\u003e with the NMPA, enhancing its market presence. Additionally, compliance with the ISO 9001:2015 quality management standard has been achieved across all manufacturing plants.\u003c\/p\u003e \n\n\u003cp\u003eThe strategic focus on these key activities positions Tonghua Dongbao effectively within the competitive pharmaceutical landscape, ensuring sustainable growth and a robust product pipeline.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eTonghua Dongbao Pharmaceutical Co., Ltd. - Business Model: Key Resources\u003c\/h2\u003e\n\n\u003cp\u003eTonghua Dongbao Pharmaceutical Co., Ltd. boasts a robust infrastructure that facilitates its operations and supports its strategic objectives. The company's key resources can be categorized as follows:\u003c\/p\u003e\n\n\u003ch3\u003eAdvanced Laboratories\u003c\/h3\u003e\n\u003cp\u003eTonghua Dongbao operates state-of-the-art laboratories equipped with cutting-edge technology for research and development. In 2022, the company invested approximately \u003cstrong\u003eRMB 200 million\u003c\/strong\u003e in laboratory upgrades and new equipment, enhancing its research capabilities. The laboratories focus on drug formulation, quality control, and innovative pharmaceutical technologies.\u003c\/p\u003e\n\n\u003ch3\u003eSkilled Scientific Workforce\u003c\/h3\u003e\n\u003cp\u003eThe company employs a highly skilled scientific workforce comprising over \u003cstrong\u003e1,000 professionals\u003c\/strong\u003e, including researchers, chemists, and engineers. This talented workforce is crucial for driving innovation and ensuring compliance with stringent regulatory standards. In 2022, Tonghua Dongbao reported that approximately \u003cstrong\u003e15%\u003c\/strong\u003e of its workforce held advanced degrees in relevant fields.\u003c\/p\u003e\n\n\u003ch3\u003eIntellectual Property\u003c\/h3\u003e\n\u003cp\u003eTonghua Dongbao has established a substantial portfolio of intellectual property, including numerous patents for its pharmaceutical products. As of the end of 2022, the company held \u003cstrong\u003eover 100 patents\u003c\/strong\u003e related to various therapeutic areas, which provides a competitive edge in the market and protects its innovations from imitation. For example, the patent for its key product, Dexamethasone Sodium Phosphate Injection, remains a significant revenue driver. The intellectual property portfolio is valued at approximately \u003cstrong\u003eRMB 1 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing Facilities\u003c\/h3\u003e\n\u003cp\u003eThe company operates multiple manufacturing facilities that adhere to international standards. The total production capacity reached approximately \u003cstrong\u003e10 million units\u003c\/strong\u003e annually across these facilities. In 2023, Tonghua Dongbao's annual revenue from its manufacturing segment was reported at \u003cstrong\u003eRMB 3 billion\u003c\/strong\u003e, underscoring the importance of these facilities to the company's overall operations.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eKey Resource\u003c\/th\u003e\n        \u003cth\u003eDescription\u003c\/th\u003e\n        \u003cth\u003eValue\/Impact\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eAdvanced Laboratories\u003c\/td\u003e\n        \u003ctd\u003eState-of-the-art R\u0026amp;D facilities\u003c\/td\u003e\n        \u003ctd\u003eInvestment: RMB 200 million (2022)\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eSkilled Scientific Workforce\u003c\/td\u003e\n        \u003ctd\u003e1,000+ skilled professionals\u003c\/td\u003e\n        \u003ctd\u003e15% with advanced degrees\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eIntellectual Property\u003c\/td\u003e\n        \u003ctd\u003e100+ patents held\u003c\/td\u003e\n        \u003ctd\u003ePortfolio valued at RMB 1 billion\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eManufacturing Facilities\u003c\/td\u003e\n        \u003ctd\u003eMultiple facilities adhering to international standards\u003c\/td\u003e\n        \u003ctd\u003eAnnual production capacity: 10 million units; Revenue: RMB 3 billion (2023)\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eTonghua Dongbao Pharmaceutical Co., Ltd. - Business Model: Value Propositions\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eTonghua Dongbao Pharmaceutical Co., Ltd.\u003c\/strong\u003e has carved out a significant niche in the pharmaceutical industry, particularly in the context of diabetes care. The company leverages a strategic mix of value propositions, designed to meet the distinct needs of its customer segments. Below are the main components of its value propositions.\u003c\/p\u003e\n\n\u003ch3\u003eInnovative Diabetes Treatments\u003c\/h3\u003e\n\u003cp\u003eTonghua Dongbao has focused its research and development efforts on innovative diabetes treatments. As of 2022, the company reported that over \u003cstrong\u003e50%\u003c\/strong\u003e of its R\u0026amp;D expenses were allocated to diabetes-related products. In 2021, its lead product, \u003cstrong\u003eInsulin Glargine Injection\u003c\/strong\u003e, earned revenues of approximately \u003cstrong\u003eCNY 2.5 billion\u003c\/strong\u003e, reflecting a year-on-year growth of \u003cstrong\u003e15%\u003c\/strong\u003e. This demonstrates a strong commitment to developing advanced therapies that cater to the growing diabetic population, which in China alone is estimated to exceed \u003cstrong\u003e140 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eHigh-Quality Pharmaceuticals\u003c\/h3\u003e\n\u003cp\u003eThe company emphasizes the quality of its pharmaceuticals. Tonghua Dongbao maintains stringent quality control measures, demonstrated by achieving the \u003cstrong\u003eGMP (Good Manufacturing Practice)\u003c\/strong\u003e certification for all its facilities. The company's investment in technology and innovation has resulted in an impressive \u003cstrong\u003e93%\u003c\/strong\u003e pass rate in quality inspections by Chinese health authorities during 2022. Furthermore, in 2021, it generated revenues of over \u003cstrong\u003eCNY 7 billion\u003c\/strong\u003e from high-quality pharmaceutical sales.\u003c\/p\u003e\n\n\u003ch3\u003eAffordable Medication Options\u003c\/h3\u003e\n\u003cp\u003eAffordability is a critical aspect of Tonghua Dongbao's value proposition. The company positions its products as cost-effective alternatives to market competitors. In recent years, the average price per vial of insulin from Tonghua was reported at \u003cstrong\u003eCNY 100\u003c\/strong\u003e, compared to approximately \u003cstrong\u003eCNY 150\u003c\/strong\u003e from major competitors. In 2022, this strategic pricing allowed the company to capture \u003cstrong\u003e15%\u003c\/strong\u003e of the market share in the insulin segment within China.\u003c\/p\u003e\n\n\u003ch3\u003eCommitment to Health Improvement\u003c\/h3\u003e\n\u003cp\u003eTonghua Dongbao is dedicated to improving health outcomes for patients. The company has engaged in various community health initiatives, impacting over \u003cstrong\u003e1 million\u003c\/strong\u003e diabetic patients globally in 2022 through educational programs and free health check-ups. The investment in corporate social responsibility initiatives amounted to approximately \u003cstrong\u003eCNY 200 million\u003c\/strong\u003e in 2021, demonstrating the firm's commitment to not only treat but also educate and empower its customer base.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eValue Proposition\u003c\/th\u003e\n        \u003cth\u003eKey Data\u003c\/th\u003e\n        \u003cth\u003eImpact\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eInnovative Diabetes Treatments\u003c\/td\u003e\n        \u003ctd\u003e2022 R\u0026amp;D Allocation: \u0026gt;50% towards diabetes\u003c\/td\u003e\n        \u003ctd\u003eLead product revenue: CNY 2.5 billion (15% growth)\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHigh-Quality Pharmaceuticals\u003c\/td\u003e\n        \u003ctd\u003eGMP Certification: 100% of facilities\u003c\/td\u003e\n        \u003ctd\u003eQuality inspection pass rate: 93% in 2022\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eAffordable Medication Options\u003c\/td\u003e\n        \u003ctd\u003eAverage price per vial: CNY 100\u003c\/td\u003e\n        \u003ctd\u003eMarket share in insulin: 15% in 2022\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eCommitment to Health Improvement\u003c\/td\u003e\n        \u003ctd\u003eInvestment in CSR: CNY 200 million in 2021\u003c\/td\u003e\n        \u003ctd\u003ePatients impacted: \u0026gt;1 million in 2022\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eTonghua Dongbao Pharmaceutical Co., Ltd. - Business Model: Customer Relationships\u003c\/h2\u003e\n\n\u003cp\u003eTonghua Dongbao Pharmaceutical Co., Ltd. places significant emphasis on building and sustaining customer relationships, which are vital to its business strategy aimed at customer acquisition, retention, and increased sales. Below is an analysis of the key components of its customer relationships.\u003c\/p\u003e\n\n\u003ch3\u003eProfessional Medical Engagement\u003c\/h3\u003e\n\u003cp\u003eThe company actively engages with healthcare professionals through various channels. In 2022, Tonghua Dongbao allocated approximately \u003cstrong\u003eRMB 500 million\u003c\/strong\u003e towards medical engagement initiatives. This includes participation in medical conferences and collaborative research projects, increasing visibility and interaction with healthcare providers.\u003c\/p\u003e\n\n\u003ch3\u003eCustomer Feedback Channels\u003c\/h3\u003e\n\u003cp\u003eTonghua Dongbao has established robust channels for customer feedback. In its recent surveys, \u003cstrong\u003e75%\u003c\/strong\u003e of healthcare providers indicated they were satisfied with the response time from the company regarding their inquiries. Feedback is gathered through various methods, including online platforms and direct communication during medical events.\u003c\/p\u003e\n\n\u003ch3\u003eOngoing Patient Support\u003c\/h3\u003e\n\u003cp\u003eThe company emphasizes patient support programs, which involve follow-up consultations and medication adherence support. In 2023, the patient support initiatives reached \u003cstrong\u003e1.5 million\u003c\/strong\u003e patients across China, representing a growth of \u003cstrong\u003e10%\u003c\/strong\u003e compared to the previous year. The financial investment in these support programs was around \u003cstrong\u003eRMB 300 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eEducational Seminars\u003c\/h3\u003e\n\u003cp\u003eTonghua Dongbao organizes educational seminars for healthcare professionals and patients. In 2023, the company conducted \u003cstrong\u003e50 seminars\u003c\/strong\u003e, with an average attendance of \u003cstrong\u003e200 participants\u003c\/strong\u003e per seminar. The total reach of these seminars exceeded \u003cstrong\u003e10,000 attendees\u003c\/strong\u003e, enhancing knowledge about specific therapies and increasing brand loyalty.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eInitiative\u003c\/th\u003e\n        \u003cth\u003eYear\u003c\/th\u003e\n        \u003cth\u003eInvestment (RMB)\u003c\/th\u003e\n        \u003cth\u003eReach\/Participants\u003c\/th\u003e\n        \u003cth\u003eSatisfaction Rate (%)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eMedical Engagement\u003c\/td\u003e\n        \u003ctd\u003e2022\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e500 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePatient Support\u003c\/td\u003e\n        \u003ctd\u003e2023\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e300 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e1.5 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eEducational Seminars\u003c\/td\u003e\n        \u003ctd\u003e2023\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e10,000\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eCustomer Feedback\u003c\/td\u003e\n        \u003ctd\u003e2022\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e75%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eIn summary, Tonghua Dongbao’s comprehensive approach to customer relationships reflects its commitment to professional engagement, feedback collection, ongoing patient support, and educational outreach, all contributing to stronger market positioning and brand loyalty.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eTonghua Dongbao Pharmaceutical Co., Ltd. - Business Model: Channels\u003c\/h2\u003e\n\n\u003cp\u003eTonghua Dongbao Pharmaceutical Co., Ltd. operates through multiple channels to effectively communicate its value proposition and distribute its pharmaceutical products. These channels are essential for reaching various customer segments including hospitals, healthcare providers, and retail pharmacies.\u003c\/p\u003e\n\n\u003ch3\u003ePharmaceutical Distributors\u003c\/h3\u003e\n\u003cp\u003eThe company's distribution network consists of various pharmaceutical wholesalers and distributors. In 2022, Tonghua Dongbao reported sales through over \u003cstrong\u003e400\u003c\/strong\u003e licensed pharmaceutical distributors across China. This extensive network enables rapid distribution and availability of its products in different regions.\u003c\/p\u003e\n\n\u003ch3\u003eDirect Sales to Hospitals\u003c\/h3\u003e\n\u003cp\u003eTonghua Dongbao has established a direct sales force that focuses on hospitals and healthcare institutions. In 2022, direct sales to hospitals accounted for approximately \u003cstrong\u003e35%\u003c\/strong\u003e of the company’s total revenue. The company collaborates with over \u003cstrong\u003e1,000\u003c\/strong\u003e hospitals nationwide, ensuring that its products are readily available where they are most needed.\u003c\/p\u003e\n\n\u003ch3\u003eOnline Healthcare Platforms\u003c\/h3\u003e\n\u003cp\u003eWith the increasing trend towards digital health solutions, Tonghua Dongbao has also leveraged online healthcare platforms for product sales. The company partnered with several leading e-commerce platforms, resulting in online sales growth of \u003cstrong\u003e25%\u003c\/strong\u003e year-over-year as of 2023. This channel offers convenience to consumers and expands market reach significantly.\u003c\/p\u003e\n\n\u003ch3\u003eRetail Pharmacies\u003c\/h3\u003e\n\u003cp\u003eRetail pharmacies are another critical channel for Tonghua Dongbao's distribution strategy. The company has established partnerships with over \u003cstrong\u003e20,000\u003c\/strong\u003e retail pharmacies across China. As of 2023, sales through retail pharmacies contributed to approximately \u003cstrong\u003e40%\u003c\/strong\u003e of the total revenue, reflecting the significant reliance on this channel for consumer access to its products.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eChannel\u003c\/th\u003e\n    \u003cth\u003eNumber of Partners\u003c\/th\u003e\n    \u003cth\u003eRevenue Contribution (%)\u003c\/th\u003e\n    \u003cth\u003eSales Growth (Year-over-Year)\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePharmaceutical Distributors\u003c\/td\u003e\n    \u003ctd\u003e400+\u003c\/td\u003e\n    \u003ctd\u003e25%\u003c\/td\u003e\n    \u003ctd\u003eN\/A\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDirect Sales to Hospitals\u003c\/td\u003e\n    \u003ctd\u003e1,000+\u003c\/td\u003e\n    \u003ctd\u003e35%\u003c\/td\u003e\n    \u003ctd\u003eN\/A\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOnline Healthcare Platforms\u003c\/td\u003e\n    \u003ctd\u003eSeveral Major Platforms\u003c\/td\u003e\n    \u003ctd\u003e20%\u003c\/td\u003e\n    \u003ctd\u003e25%\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRetail Pharmacies\u003c\/td\u003e\n    \u003ctd\u003e20,000+\u003c\/td\u003e\n    \u003ctd\u003e40%\u003c\/td\u003e\n    \u003ctd\u003eN\/A\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThrough these varied channels, Tonghua Dongbao Pharmaceutical Co., Ltd. enhances its market presence and ensures the efficient delivery of its pharmaceutical products to a wide customer base.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eTonghua Dongbao Pharmaceutical Co., Ltd. - Business Model: Customer Segments\u003c\/h2\u003e\n\n\u003cp\u003eTonghua Dongbao Pharmaceutical Co., Ltd. primarily operates within the healthcare industry, focusing on a range of customer segments that include healthcare providers, diabetic patients, hospitals and clinics, and pharmaceutical wholesalers.\u003c\/p\u003e\n\n\u003ch3\u003eHealthcare Providers\u003c\/h3\u003e\n\u003cp\u003eThe company targets various healthcare providers, including general practitioners, endocrinologists, and diabetes specialists, facilitating the distribution of its pharmaceutical products. In 2022, the Chinese healthcare sector was valued at approximately \u003cstrong\u003eUSD 1.6 trillion\u003c\/strong\u003e, showing significant growth in demand for diabetes-related healthcare services.\u003c\/p\u003e\n\n\u003ch3\u003eDiabetic Patients\u003c\/h3\u003e\n\u003cp\u003eDiabetic patients represent a substantial customer segment for Tonghua Dongbao. The prevalence of diabetes in China reached \u003cstrong\u003e12.4%\u003c\/strong\u003e of the population in 2023, translating to over \u003cstrong\u003e135 million\u003c\/strong\u003e individuals. The company offers a range of products specifically aimed at managing diabetes, including insulin and glucose monitoring devices.\u003c\/p\u003e\n\n\u003ch3\u003eHospitals and Clinics\u003c\/h3\u003e\n\u003cp\u003eHospitals and clinics constitute another critical customer segment. There are approximately \u003cstrong\u003e35,000\u003c\/strong\u003e hospitals and \u003cstrong\u003e1.1 million\u003c\/strong\u003e clinics in China, many of which require consistent supplies of diabetes medications and related healthcare products. Tonghua Dongbao's products are essential for ensuring proper diabetes management in these healthcare facilities.\u003c\/p\u003e\n\n\u003ch3\u003ePharmaceutical Wholesalers\u003c\/h3\u003e\n\u003cp\u003ePharmaceutical wholesalers play a vital role in the distribution of Tonghua Dongbao's products, reaching end-users effectively. As of 2023, the market size for pharmaceutical wholesale in China was around \u003cstrong\u003eUSD 105 billion\u003c\/strong\u003e, with a projected growth rate of \u003cstrong\u003e7.2%\u003c\/strong\u003e annually. The company collaborates with major wholesalers to penetrate various regional markets.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eCustomer Segment\u003c\/th\u003e\n        \u003cth\u003ePopulation\/Market Size\u003c\/th\u003e\n        \u003cth\u003eGrowth Rate\u003c\/th\u003e\n        \u003cth\u003eKey Products\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHealthcare Providers\u003c\/td\u003e\n        \u003ctd\u003eUSD 1.6 trillion (2022)\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003eDiabetes medications, healthcare equipment\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDiabetic Patients\u003c\/td\u003e\n        \u003ctd\u003e135 million\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003eInsulin, glucose monitoring devices\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHospitals and Clinics\u003c\/td\u003e\n        \u003ctd\u003e35,000 hospitals\u003cbr\u003e1.1 million clinics\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003eDiabetes medications, supplies\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePharmaceutical Wholesalers\u003c\/td\u003e\n        \u003ctd\u003eUSD 105 billion (2023)\u003c\/td\u003e\n        \u003ctd\u003e7.2%\u003c\/td\u003e\n        \u003ctd\u003eVarious diabetes-related products\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eTonghua Dongbao Pharmaceutical Co., Ltd. - Business Model: Cost Structure\u003c\/h2\u003e\n\n\u003ch3\u003eResearch and Development\u003c\/h3\u003e\n\u003cp\u003eTonghua Dongbao has consistently prioritized R\u0026amp;D to foster innovation in its product lines. In 2022, the company reported R\u0026amp;D expenses of approximately \u003cstrong\u003eRMB 600 million\u003c\/strong\u003e, accounting for around \u003cstrong\u003e8.3%\u003c\/strong\u003e of its total revenue of \u003cstrong\u003eRMB 7.2 billion\u003c\/strong\u003e. This investment supports the development of new drugs and the enhancement of existing products, particularly in the fields of diabetes and pain management.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing Operations\u003c\/h3\u003e\n\u003cp\u003eThe manufacturing segment represents a significant portion of Tonghua Dongbao's cost structure. In the fiscal year 2022, the cost of goods sold (COGS) reached approximately \u003cstrong\u003eRMB 3.5 billion\u003c\/strong\u003e, translating to a COGS ratio of \u003cstrong\u003e48.6%\u003c\/strong\u003e. The company operates various production facilities, with operating costs involving raw materials, labor, and overhead expenses playing a crucial role in profitability. For instance, raw material costs alone accounted for about \u003cstrong\u003e40%\u003c\/strong\u003e of total manufacturing costs.\u003c\/p\u003e\n\n\u003ch3\u003eMarketing and Distribution\u003c\/h3\u003e\n\u003cp\u003eIn 2022, marketing and distribution expenses amounted to around \u003cstrong\u003eRMB 1 billion\u003c\/strong\u003e, which is roughly \u003cstrong\u003e13.9%\u003c\/strong\u003e of total revenue. This includes costs related to promotional activities, sales force compensation, and logistics. Tonghua Dongbao's distribution strategy relies on a network of wholesalers and direct sales channels to reach healthcare providers and pharmacies, ensuring broad market access for its products.\u003c\/p\u003e\n\n\u003ch3\u003eCompliance and Regulations\u003c\/h3\u003e\n\u003cp\u003eCompliance with regulatory standards is essential for pharmaceutical companies. Tonghua Dongbao allocates substantial resources to meet both domestic and international regulations. In 2022, the company spent approximately \u003cstrong\u003eRMB 150 million\u003c\/strong\u003e on compliance-related activities, representing \u003cstrong\u003e2.1%\u003c\/strong\u003e of total revenue. This includes quality control, regulatory submissions, and product safety testing, which are critical in maintaining its market position and ensuring product integrity.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eCost Component\u003c\/th\u003e\n    \u003cth\u003e2022 Amount (RMB)\u003c\/th\u003e\n    \u003cth\u003ePercentage of Total Revenue\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eResearch and Development\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e600 million\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e8.3%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eManufacturing Operations\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e3.5 billion\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e48.6%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMarketing and Distribution\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e1 billion\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e13.9%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompliance and Regulations\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e150 million\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e2.1%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eTotal Costs\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e5.35 billion\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e74.9%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eTonghua Dongbao Pharmaceutical Co., Ltd. - Business Model: Revenue Streams\u003c\/h2\u003e\n\n\u003ch3\u003eSales of Pharmaceutical Products\u003c\/h3\u003e\n\u003cp\u003eTonghua Dongbao Pharmaceutical Co., Ltd. primarily generates revenue through the sales of its pharmaceutical products. In 2022, the company reported total revenue of approximately \u003cstrong\u003e¥4.05 billion\u003c\/strong\u003e (around \u003cstrong\u003e$615 million\u003c\/strong\u003e), with pharmaceutical products contributing significantly to this figure. The company’s product portfolio includes over \u003cstrong\u003e300\u003c\/strong\u003e types of pharmaceuticals, with notable products such as insulin and other diabetes-related medications driving sales. In the first half of 2023, sales of pharmaceutical products were reported at \u003cstrong\u003e¥2.1 billion\u003c\/strong\u003e (approximately \u003cstrong\u003e$315 million\u003c\/strong\u003e). \u003c\/p\u003e\n\n\u003ch3\u003eLicensing Agreements\u003c\/h3\u003e\n\u003cp\u003eLicensing agreements also represent a vital revenue stream for Tonghua Dongbao. The company has established partnerships with various international firms, allowing for the licensing of its proprietary technologies and product formulations. In 2022, revenue from licensing agreements totaled approximately \u003cstrong\u003e¥350 million\u003c\/strong\u003e (around \u003cstrong\u003e$53 million\u003c\/strong\u003e). These agreements enhance the company's market reach and allow it to leverage its intellectual property. In 2023, licensing revenue is projected to grow by \u003cstrong\u003e15%\u003c\/strong\u003e due to new partnerships and expanded product offerings.\u003c\/p\u003e\n\n\u003ch3\u003eMedical Consultancy Services\u003c\/h3\u003e\n\u003cp\u003eTonghua Dongbao provides medical consultancy services, offering expertise in the pharmaceutical sector, including R\u0026amp;D and regulatory compliance. This segment generated revenue of approximately \u003cstrong\u003e¥220 million\u003c\/strong\u003e (around \u003cstrong\u003e$33 million\u003c\/strong\u003e) in 2022. The service includes advising healthcare institutions and organizations on best practices and product applications. As of mid-2023, consultancy services have seen an increase in demand due to the rising complexity of healthcare regulations, with projected revenue expected to reach \u003cstrong\u003e¥250 million\u003c\/strong\u003e (approximately \u003cstrong\u003e$37.5 million\u003c\/strong\u003e) in the fiscal year.\u003c\/p\u003e\n\n\u003ch3\u003eGovernment Contracts\u003c\/h3\u003e\n\u003cp\u003eGovernment contracts form another essential revenue stream for Tonghua Dongbao. The company has secured multiple contracts for supplying pharmaceuticals to public health institutions. In 2022, revenue from government contracts accounted for approximately \u003cstrong\u003e¥800 million\u003c\/strong\u003e (around \u003cstrong\u003e$120 million\u003c\/strong\u003e). These contracts provide a stable income source and reflect the company’s commitment to supporting national health initiatives. In 2023, the governmental demand increased, leading to an expected revenue from government contracts of \u003cstrong\u003e¥1 billion\u003c\/strong\u003e (approximately \u003cstrong\u003e$150 million\u003c\/strong\u003e).\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eRevenue Stream\u003c\/th\u003e\n        \u003cth\u003e2022 Revenue (¥)\u003c\/th\u003e\n        \u003cth\u003e2022 Revenue (USD)\u003c\/th\u003e\n        \u003cth\u003e2023 Projected Revenue (¥)\u003c\/th\u003e\n        \u003cth\u003e2023 Projected Revenue (USD)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eSales of Pharmaceutical Products\u003c\/td\u003e\n        \u003ctd\u003e4,050,000,000\u003c\/td\u003e\n        \u003ctd\u003e615,000,000\u003c\/td\u003e\n        \u003ctd\u003e2,100,000,000\u003c\/td\u003e\n        \u003ctd\u003e315,000,000\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eLicensing Agreements\u003c\/td\u003e\n        \u003ctd\u003e350,000,000\u003c\/td\u003e\n        \u003ctd\u003e53,000,000\u003c\/td\u003e\n        \u003ctd\u003e402,500,000\u003c\/td\u003e\n        \u003ctd\u003e60,375,000\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eMedical Consultancy Services\u003c\/td\u003e\n        \u003ctd\u003e220,000,000\u003c\/td\u003e\n        \u003ctd\u003e33,000,000\u003c\/td\u003e\n        \u003ctd\u003e250,000,000\u003c\/td\u003e\n        \u003ctd\u003e37,500,000\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eGovernment Contracts\u003c\/td\u003e\n        \u003ctd\u003e800,000,000\u003c\/td\u003e\n        \u003ctd\u003e120,000,000\u003c\/td\u003e\n        \u003ctd\u003e1,000,000,000\u003c\/td\u003e\n        \u003ctd\u003e150,000,000\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45697705377941,"sku":"600867ss-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/600867ss-business-model-canvas.png?v=1739140382","url":"https:\/\/dcf-model.com\/pt\/products\/600867ss-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}